Corcept Therapeutics ( CORT) dropped on the failure of a late-phase trial of its Corlux treatment for psychotic major depression. The drug didn't meet its primary endpoint, which dictated at least a 50% improvement in symptoms as measured by the Psychiatric Rating Scale Positive Symptom Subscale. Shares were sinking 11 cents, or 10.4%, to 93 cents.

Omnova Solutions ( OMN) widened its first-quarter loss to $5.1 million, or 12 cents a share, from a loss of $4.3 million, or a dime a share, a year ago. Analysts polled by Thomson Financial were looking for a loss of 2 cents a share. Revenue slipped year over year to $164.8 million -- $7.2 million under the only analyst's estimate. Shares were off 18 cents, or 2.8%, to $6.17.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk